{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:36:51Z","timestamp":1790836611263,"version":"4.1.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>It is well known that some serotoninergic drugs and neuroendocrine tumors producing serotonin (5-HT) may induce valvular heart disease by stimulation of proliferation of valvular cells <jats:italic>via<\/jats:italic> interaction with a 5-HT receptor type 2B. Serotonin could play a role in the pathogenesis of progressive valvular disease for example as a complication of rheumatic fever, in patients with congenital bicuspid aortic valves or in degenerative aortic valve stenosis. The initial inflammation in acute rheumatic fever seems to affect both right and the left-side cardiac valves. Some patients develop chronic right-sided valve disease, particularly in connection with septum defects, though left-sided valves typically are predominantly affected, indicating that high flow velocity and systemic pressure close to the valves may be central in the pathogenesis. Serotonin is transported in granules in blood platelets. Changes in platelet number and concentrations of substances released from platelets in patients with valvular disease indicate that serotonin is released locally by shear stress when passing through an abnormal valve. Accordingly, any functional changes (like bicuspid aortic valves and changes secondary to degeneration) in the valves may progress due to locally released serotonin. Unfortunately, due to serotonin release by sampling and preparation of plasma, local serotonin assessment is not possible. Nevertheless, we suggest that serotonin may play a role in valvular disease in general and that patients may benefit from treatment reducing the effect of serotonin on the heart.<\/jats:p>","DOI":"10.3389\/fcvm.2022.774573","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T05:52:50Z","timestamp":1643349170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Serotonin\u2014A Driver of Progressive Heart Valve Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Helge","family":"Waldum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJMoa1603693","article-title":"Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015","volume":"377","author":"Watkins","year":"2017","journal-title":"N Engl J Med."},{"key":"B2","first-page":"264","article-title":"Bicuspid aortic valve","volume":"8","author":"Yener","year":"2002","journal-title":"Ann Thorac Cardiovasc Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000507847","article-title":"Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management","volume":"146","author":"Jin","year":"2021","journal-title":"Cardiology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1038\/nrdp.2015.84","article-title":"Acute rheumatic fever and rheumatic heart disease","volume":"2","author":"Carapetis","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/BOR.0b013e32835461d3","article-title":"Streptococcus and rheumatic fever","volume":"24","author":"Cunningham","year":"2012","journal-title":"Curr Opin Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1017\/S1047951101000269","article-title":"Can subclinical valvitis detected by echocardiography be accepted as evidence of carditis in the diagnosis of acute rheumatic fever?","volume":"11","author":"Ozkutlu","year":"2001","journal-title":"Cardiol Young."},{"key":"B7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.acvd.2019.04.003","article-title":"Pathophysiology and management of combined aortic and mitral regurgitation","volume":"112","author":"Unger","year":"2019","journal-title":"Arch Cardiovasc Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.24911\/SJP.2017.2.9","article-title":"Lutembacher syndrome variant: rheumatic heart disease involving all four valves and associated with an atrial septal defect in a child","volume":"17","author":"Karadawi","year":"2017","journal-title":"Sudan J Paediatr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/hrt.74.6.641","article-title":"Decreased platelet function in aortic valve stenosis: high shear platelet activation then inactivation","volume":"74","author":"O'Brien","year":"1995","journal-title":"Br Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s10237-012-0375-x","article-title":"Computational assessment of bicuspid aortic valve wall-shear stress: implications for calcific aortic valve disease","volume":"11","author":"Chandra","year":"2012","journal-title":"Biomech Model Mechanobiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ijcard.2008.02.019","article-title":"Carcinoid heart disease","volume":"129","author":"Gustafsson","year":"2008","journal-title":"Int J Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.phrs.2018.08.005","article-title":"Serotonin, hematopoiesis and stem cells","volume":"140","author":"Fouquet","year":"2019","journal-title":"Pharmacol Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1002\/cncr.31079","article-title":"Neuroendocrine tumors and fibrosis: an unsolved mystery?","volume":"123","author":"Laskaratos","year":"2017","journal-title":"Cancer."},{"key":"B14","first-page":"827","article-title":"Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects","volume":"10","author":"Rajamannan","year":"2001","journal-title":"J Heart Valve Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1161\/01.CIR.0000159356.42064.48","article-title":"Long-term serotonin administration induces heart valve disease in rats","volume":"111","author":"Gustafsson","year":"2005","journal-title":"Circulation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1050-1738(01)00135-9","article-title":"A novel role for serotonin in heart","volume":"11","author":"Nebigil","year":"2001","journal-title":"Trends Cardiovasc Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.regpep.2007.02.009","article-title":"Long-term serotonin effects in the rat are prevented by terguride","volume":"143","author":"Hauso","year":"2007","journal-title":"Regul Pept."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/S0002-9440(10)64497-5","article-title":"Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells","volume":"161","author":"Xu","year":"2002","journal-title":"Am J Pathol."},{"key":"B19","first-page":"75","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.33549\/physiolres.931903","article-title":"Serotonin receptors - from molecular biology to clinical applications","volume":"60","author":"Pytliak","year":"2011","journal-title":"Physiol Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.pharmthera.2005.12.004","article-title":"5-hydroxytryptamine receptors in the human cardiovascular system","volume":"111","author":"Kaumann","year":"2006","journal-title":"Pharmacol Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease\u2013it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: an update","volume":"38","author":"Elangbam","year":"2010","journal-title":"Toxicol Pathol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3181\/00379727-97-23734","article-title":"Dermal fibrosis following subcutaneous injections of serotonin creatinine sulphate","volume":"97","author":"Macdonald","year":"1958","journal-title":"Proc Soc Exp Biol Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/S0002-9440(10)64489-6","article-title":"Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells","volume":"161","author":"Jian","year":"2002","journal-title":"Am J Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.bjp.0703570","article-title":"5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension","volume":"131","author":"MacLean","year":"2000","journal-title":"Br J Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1440-1681.2006.04410.x","article-title":"5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter","volume":"33","author":"Ni","year":"2006","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1161\/CIRCULATIONAHA.105.554667","article-title":"Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice","volume":"113","author":"Mekontso-Dessap","year":"2006"},{"key":"B29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jcb.29847","article-title":"Serotonin receptor type 2B activation augments TNF-\u03b1-induced matrix mineralization in murine valvular interstitial cells","volume":"122","author":"Fong","year":"2021","journal-title":"J Cell Biochem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/eurheartj\/ehy696","article-title":"Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis","volume":"40","author":"Bouchareb","year":"2019","journal-title":"Eur Heart J."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10237-021-01527-4.","article-title":"Impact of calcific aortic valve disease on valve mechanics","author":"Vogl","year":"2021","journal-title":"Biomech Model Mechanobiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"10730","DOI":"10.1074\/jbc.M309426200","article-title":"Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets","volume":"279","author":"Shirakawa","year":"2004","journal-title":"J Biol Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0049-3848(83)90162-7","article-title":"Efflux of granule constituents from platelets exposed to different mechanical forces","volume":"32","author":"Stavenow","year":"1983","journal-title":"Thromb Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1046\/j.1365-2796.2002.01062.x","article-title":"Acquired platelet dysfunction may be an aetiologic factor in Heyde's syndrome\u2013normalization of bleeding time after aortic valve replacement","volume":"252","author":"Olsson","year":"2002","journal-title":"J Intern Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcin.2018.09.041","article-title":"Blood disorders in patients undergoing transcatheter aortic valve replacement: a review","volume":"12","author":"De Larochelli\u00e8re","year":"2019","journal-title":"JACC Cardiovasc Interv."},{"key":"B36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1056\/NEJMoa022831","article-title":"Acquired von Willebrand syndrome in aortic stenosis","volume":"349","author":"Vincentelli","year":"2003","journal-title":"N Engl J Med."},{"key":"B37","first-page":"542","article-title":"Prevalent platelet dysfunction in patients with aortic valve disease","volume":"17","author":"Prohaska","year":"2008","journal-title":"J Heart Valve Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.20101629","article-title":"Platelet-derived serotonin links vascular disease and tissue fibrosis","volume":"208","author":"Dees","year":"2011","journal-title":"J Exp Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1517\/14740330902931524","article-title":"Serotonergic drugs and valvular heart disease","volume":"8","author":"Rothman","year":"2009","journal-title":"Expert Opin Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/14017431.2014.886335","article-title":"Venous plasma serotonin is not a proper biomarker for pulmonary arterial hypertension","volume":"48","author":"Zeinali","year":"2014","journal-title":"Scand Cardiovasc J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00277-020-04170-8","article-title":"Idiopathic thrombocytopenic purpura is strongly associated with higher prevalence of aortic valve disease","volume":"99","author":"Haseefa","year":"2020","journal-title":"Ann Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2174\/1573403X14666180820151325","article-title":"Cellular mechanisms of valvular thickening in early and intermediate calcific aortic valve disease","volume":"14","author":"Ohukainen","year":"2018","journal-title":"Curr Cardiol Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e015610","DOI":"10.1161\/JAHA.119.015610","article-title":"Age, sex, and valve phenotype differences in fibro-calcific remodeling of calcified aortic valve","volume":"9","author":"Voisine","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"19494","DOI":"10.1021\/acsomega.1c01723","article-title":"Comparison of serotonin-regulated calcific processes in aortic and mitral valvular interstitial cells","volume":"6","author":"Wang","year":"2021","journal-title":"ACS Omega."},{"key":"B45","doi-asserted-by":"publisher","first-page":"20366","DOI":"10.1002\/jcp.28638","article-title":"The methylation of Notch1 promoter mediates the osteogenesis differentiation in human aortic valve interstitial cells through Wnt\/\u03b2-catenin signaling","volume":"234","author":"Zhou","year":"2019","journal-title":"J Cell Physiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e0238407","DOI":"10.1371\/journal.pone.0238407","article-title":"Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of Notch1 heterozygous mice in a high-cholesterol diet model","volume":"15","author":"Joll","year":"2020","journal-title":"PLoS ONE."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1161\/CIRCULATIONAHA.116.023997","article-title":"Medical treatment of aortic stenosis","volume":"134","author":"Marquis-Gravel","year":"2016","journal-title":"Circulation."},{"key":"B48","doi-asserted-by":"publisher","first-page":"107196","DOI":"10.1016\/j.carpath.2019.107196","article-title":"Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-\u03b2 mechanisms","volume":"46","author":"Oyama","year":"2020","journal-title":"Cardiovasc Pathol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.phrs.2018.09.009","article-title":"Serotonin contribution to cardiac valve degeneration: new insights for novel therapies?","volume":"140","author":"Ayme-Dietrich","year":"2019","journal-title":"Pharmacol Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/cvr\/cvx092","article-title":"Serotonin and catecholamines in the development and progression of heart valve diseases","volume":"113","author":"Goldberg","year":"2017","journal-title":"Cardiovasc Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12012-009-9046-2","article-title":"Dose dependency and reversibility of serotonin-induced valvular heart disease in rats","volume":"9","author":"Droogmans","year":"2009","journal-title":"Cardiovasc Toxicol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1210\/jc.2014-2247","article-title":"Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial","volume":"100","author":"Pavel","year":"2015","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.774573\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T05:53:00Z","timestamp":1643349180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.774573\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":52,"alternative-id":["10.3389\/fcvm.2022.774573"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.774573","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"article-number":"774573"}}